Revolo Biotherapeutics Announces Positive Topline Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis
Data shows the achievement of the primary endpoint of decreasing esophageal intraepithelial eosinophil count and the positive impact on an array of histological measures of EoE. Favorable safety and tolerability profile consistent with Phase 1 trial results.